Testing treatments for metastatic hormone-sensitive prostate cancer
Part of Cancer clinical trials.
This trial tests two newer treatments—targeted radiation (SABR) or a special radioactive drug (Lu-177 PSMA-617)—added to standard hormone therapy for men with prostate cancer that has spread. The goal is to see if these additional treatments help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- Prostate cancer that has spread to other parts of the body (confirmed by scans like CT, MRI, or PET)
- You are starting or planning to start long-term hormone therapy (for at least 2 years)
- You are in generally good health (able to do daily activities) or any health issues are related to the cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding a radioactive drug called 177Lu-PSMA-617 to standard therapy helps men whose prostate cancer has spread and hasn't responded well to initial hormone therapy. It's for men whose PSA level is still detectable after 6-8 months of treatment.
This trial looks at whether a precise form of radiation (stereotactic body radiotherapy) can control a small number of prostate cancer spots seen on a special scan (PSMA PET/CT). It may help by treating limited metastases while avoiding unnecessary treatment elsewhere.
This trial tests a combination of two treatments for men with prostate cancer that has spread to a small number of sites: a radioactive injection (177Lu-PSMA-617) that targets cancer cells, plus hormone-blocking medication. The goal is to control the cancer and delay progression.
This trial tests whether adding radiation therapy to the prostate and cancer spread sites helps men whose prostate cancer has spread to bones but isn't responding well to standard hormone treatments. You'd be eligible if your PSA level (a cancer marker) stays high after six months of dual hormone therapy.
This trial tests whether a short course of high-dose testosterone followed by a radioactive drug (PSMA-617) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to make cancer cells more sensitive to the radiation.
This trial uses a special PET scan to find spots where prostate cancer has spread. Then, it delivers precise radiation to those spots while you receive standard hormone therapy. The goal is to see if this approach helps control the cancer.
Hear when a new Prostate Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.